MCID: KDN017
MIFTS: 60

Kidney Cancer

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 43 15
Renal Cancer 12 75 29 55 15
Renal Carcinoma 17 72
Kidney Neoplasm 17 72
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 72
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 72
Kidney Carcinoma 6
Kidney Neoplasms 44
Cancer, Kidney 40

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD9CM 35 189.0
MeSH 44 D007680
SNOMED-CT 68 93849006
ICD10 33 C64
UMLS 72 C0007134 C0022665 C0494158 more

Summaries for Kidney Cancer

MedlinePlus : 43 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Nicotine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and prostate.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 75 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 636)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 32.6 PVT1 MTOR MIR200C MIR141 MET MALAT1
2 clear cell renal cell carcinoma 31.5 PVT1 MTOR MIR21 MET MEG3 MALAT1
3 bladder cancer 30.6 RNY3 RNY1 PVT1 MIR21 MEG3 MALAT1
4 polymyositis 30.5 MIR210 MIR21
5 malignant pleural mesothelioma 30.5 PVT1 MET GAS5
6 diffuse large b-cell lymphoma 30.5 MIR210 MIR21 MIR106A HOTAIR
7 laryngeal squamous cell carcinoma 30.4 MIR21 MALAT1 HOTAIR H19
8 pituitary adenoma 30.4 MEG3 MALAT1 HOTAIR H19
9 glioblastoma multiforme 30.4 MTOR MIR210 MIR21 MET
10 small cell cancer of the lung 30.4 MIR21 MALAT1 HOTAIR
11 myeloma, multiple 30.3 PVT1 MEG3 MALAT1 HOTAIR H19 GAS5
12 prostate disease 30.3 MEG3 MALAT1 H19 GAS5
13 gallbladder cancer 30.3 MEG3 MALAT1 HOTAIR H19
14 osteoarthritis 30.3 MEG3 HOTAIR H19 GAS5
15 astrocytoma 30.3 MIR21 MIR106A HOTAIR H19
16 liver cirrhosis 30.2 MEG3 MALAT1 HOTAIR GAS5
17 osteogenic sarcoma 30.2 PVT1 MEG3 MALAT1 HOTAIR HIF1A-AS2 H19
18 leukemia, acute myeloid 30.1 MTOR MIR210 MIR21 MEG3 MALAT1 HOTAIR
19 psoriasis 30.1 MIR21 MIR141 MIR106A
20 bladder urothelial carcinoma 30.1 PVT1 MTOR MEG3 MALAT1 HOTAIR GAS5
21 oral squamous cell carcinoma 30.1 MIR21 MIR200C MEG3 MALAT1 HOTAIR H19
22 hepatocellular carcinoma 30.0 PVT1 MTOR MIR21 MIR141 MET MEG3
23 endometrial cancer 30.0 MTOR MIR200C MEG3 HOTAIR H19 GAS5
24 lung cancer susceptibility 3 30.0 MET MEG3 MALAT1 KCNQ1OT1 HOTAIR H19
25 melanoma 29.9 PVT1 MIR210 MIR200C MIR141 MIR106A MEG3
26 glioblastoma 29.8 MTOR MIR21 MET MEG3 MALAT1 HOTAIR
27 squamous cell carcinoma, head and neck 29.8 MIR210 MIR21 MIR141 MET HOTAIR H19
28 glioma 29.7 PVT1 MIR210 MIR21 MIR17 MET MEG3
29 esophageal cancer 29.6 PVT1 MIR21 MIR106A MEG3 MALAT1 KCNQ1OT1
30 pancreatic cancer 29.4 PVT1 MTOR MIR210 MIR21 MIR106A MET
31 ovarian cancer 29.3 PVT1 MIR210 MIR21 MIR200C MIR141 MEG3
32 gastric cancer 29.2 PVT1 MIR21 MIR200C MIR141 MIR106A MET
33 breast cancer 28.9 PVT1 MTOR MIR210 MIR21 MIR200C MIR141
34 prostate cancer 28.7 RNY3 RNY1 PVT1 MTOR MIR210 MIR21
35 lung cancer 28.6 RNY3 RNY1 PVT1 MIR210 MIR21 MIR200C
36 colorectal cancer 28.6 RNY3 RNY1 PVT1 MTOR MIR21 MIR200C
37 childhood multilocular cystic kidney neoplasm 12.2
38 kidney cancer, childhood 12.2
39 kidney carcinoma in situ 12.2
40 inherited renal cancer-predisposing syndrome 12.1
41 hereditary leiomyomatosis and renal cell cancer 11.6
42 chromophobe renal cell carcinoma 11.5
43 collecting duct carcinoma 11.5
44 von hippel-lindau syndrome 11.4
45 birt-hogg-dube syndrome 11.4
46 wilms tumor 5 11.4
47 mucinous tubular and spindle renal cell carcinoma 11.4
48 kidney rhabdoid cancer 11.3
49 transitional cell carcinoma 11.3
50 renal cell carcinoma, papillary, 1 11.3

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

Drugs & Therapeutics for Kidney Cancer

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Ibuprofen Approved Phase 4 15687-27-1 3672
6
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
7
Acetaminophen Approved Phase 4 103-90-2 1983
8
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
tannic acid Approved Phase 4 1401-55-4
13
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
14
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
15
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
16
Remifentanil Approved Phase 4 132875-61-7 60815
17
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
18
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
19 Analgesics Phase 4
20 Analgesics, Non-Narcotic Phase 4
21 Peripheral Nervous System Agents Phase 4
22 Antirheumatic Agents Phase 4
23 Anti-Inflammatory Agents Phase 4
24 Adrenergic Agents Phase 4
25 Cyclooxygenase Inhibitors Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Narcotics Phase 4
28 Psychotropic Drugs Phase 4
29 Adrenergic Agonists Phase 4
30 Adrenergic alpha-Agonists Phase 4
31 Nicotinic Agonists Phase 4
32 Central Nervous System Stimulants Phase 4
33 Adjuvants, Anesthesia Phase 4
34 Antidepressive Agents Phase 4
35 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
36 Antidepressive Agents, Second-Generation Phase 4
37 Neurotransmitter Uptake Inhibitors Phase 4
38 Dopamine Uptake Inhibitors Phase 4
39 Adrenergic alpha-2 Receptor Agonists Phase 4
40 Liver Extracts Phase 4
41 Anti-Arrhythmia Agents Phase 4
42 Antipyretics Phase 4
43 Analgesics, Opioid Phase 4
44 Sodium Channel Blockers Phase 4
45 Diuretics, Potassium Sparing Phase 4
46 Dexamethasone 21-phosphate Phase 4
47 Anesthetics Phase 4
48 Central Nervous System Depressants Phase 4
49 Hypnotics and Sedatives Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 1758)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
3 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
4 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
5 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
6 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
8 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
9 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
10 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
11 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
12 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
13 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
14 A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy Completed NCT03323021 Phase 4
15 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
16 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Caesarean Section. A Double Blind, Randomized, Placebo Controlled Trial. Completed NCT03068260 Phase 4 Ropivacaine;Saline;Acetaminophen;Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet;Morphine
17 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
18 A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
19 Quadratus Lumborum Block (QLB) With and Without Dexamethasone: the Effect on Postoperative Pain and Recovery After Laparoscopic Nephrectomy Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
20 Improving Postoperative Pain Management With the Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot-assisted Partiel Nephrectomy: A Double Blind, Randomized, Placebo Controlled Trial Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
21 Randomized, Double-Blind Clinical Study Evaluating Efficacy of Intravenous Versus Enteric Acetaminophen in Donor Nephrectomy and Robot-Assisted, Laparoscopic Nephrectomy. Recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
22 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
23 Safety Study of Nivolumab for Selected Advanced Malignancies in India Active, not recruiting NCT03444766 Phase 4 Nivolumab
24 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
25 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
26 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
27 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
28 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
29 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging Not yet recruiting NCT04021238 Phase 4 Perflutren lipid microsphere;Sulfur hexafluoride lipid microspheres
30 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Not yet recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
31 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
32 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
33 Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
34 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
35 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
36 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
37 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
38 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
39 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
40 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
41 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
42 A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer Unknown status NCT02044354 Phase 3 Taxotere;Jevtana
43 Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer Unknown status NCT01987596 Phase 3
44 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
45 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
46 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
47 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
48 A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00053820 Phase 3 fluorouracil
49 A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma. Completed NCT00065468 Phase 3 Interferon Alfa;CCI-779;Interferon Alfa and CCI-779
50 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Lomustine
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Cancer 29

Anatomical Context for Kidney Cancer

MalaCards organs/tissues related to Kidney Cancer:

41
Kidney, Lung, Prostate, Bone, Brain, Breast, Endothelial

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

19
Kidney

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 8941)
# Title Authors PMID Year
1
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. 38 88
19646430 2010
2
Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma. 17
31262924 2019
3
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. 17
31079938 2019
4
The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma. 17
31177102 2019
5
Multi-modal treatment for metastatic renal cancer: the role of surgery. 9 38
20364382 2010
6
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. 9 38
20091131 2010
7
The genetic basis of kidney cancer: a metabolic disease. 9 38
20448661 2010
8
Urinary biomarkers for the early diagnosis of kidney cancer. 9 38
20375178 2010
9
Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? 9 38
20435833 2010
10
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 9 38
20425594 2010
11
Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. 9 38
20155457 2010
12
Compounds in clinical Phase III and beyond. 9 38
20033382 2010
13
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 9 38
20054297 2010
14
Molecular basis for the treatment of renal cell carcinoma. 9 38
20080466 2010
15
Molecular diagnosis and therapy of kidney cancer. 9 38
20059341 2010
16
Management of vascular endothelial growth factor and multikinase inhibitor side effects. 9 38
19948455 2009
17
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage. 9 38
19706601 2009
18
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 9 38
19801515 2009
19
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 9 38
19639177 2009
20
TGF-alpha as a candidate tumor antigen for renal cell carcinomas. 9 38
19052740 2009
21
Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? 9 38
19663736 2009
22
VHL loss causes spindle misorientation and chromosome instability. 9 38
19620968 2009
23
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. 9 38
19470762 2009
24
P-glycoprotein activity in renal clear cell carcinoma. 9 38
18440836 2009
25
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. 9 38
19451442 2009
26
[Case of drug-induced colitis like ulcerative colitis during IL-2 therapy for multiple bone metastasis after operation of kidney cancer]. 9 38
19663247 2009
27
The role of antiangiogenesis therapy: bevacizumab and beyond. 9 38
19531449 2009
28
Targeting the Met signaling pathway in renal cancer. 9 38
19496715 2009
29
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. 9 38
19675744 2009
30
Hereditary kidney cancer: unique opportunity for disease-based therapy. 9 38
19402075 2009
31
Proepithelin is an autocrine growth factor for bladder cancer. 9 38
19237611 2009
32
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. 9 38
19402056 2009
33
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. 9 38
19318488 2009
34
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. 9 38
19409039 2009
35
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. 9 38
19236264 2009
36
[Hereditary renal cancer]. 9 38
19418834 2009
37
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. 9 38
19238017 2009
38
[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]. 9 38
19452104 2009
39
Implication of bevacizumab in fatal arterial thromboembolic incidents. 9 38
19365880 2009
40
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. 9 38
19165638 2009
41
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. 9 38
19891126 2008
42
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 88
18925646 2008
43
Kidney cancer: now available in a new flavor. 9 38
19061830 2008
44
Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. 9 38
18986479 2008
45
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. 9 38
18928373 2008
46
Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. 9 38
18806787 2008
47
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. 9 38
18243508 2008
48
Conclusion and future directions. 9 38
18836339 2008
49
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. 9 38
18794104 2008
50
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. 9 38
18676741 2008

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MET NM_001127500.3(MET): c.3335A> G (p.His1112Arg) single nucleotide variant Pathogenic rs121913243 7:116417464-116417464 7:116777410-116777410
2 MTOR NM_004958.4(MTOR): c.6644C> A (p.Ser2215Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587777894 1:11184573-11184573 1:11124516-11124516
3 MTOR NM_004958.4(MTOR): c.4379T> C (p.Leu1460Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519779 1:11217299-11217299 1:11157242-11157242
4 MET NM_001127500.3(MET): c.3743A> G (p.Tyr1248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913246 7:116423414-116423414 7:116783360-116783360
5 MET NM_001127500.3(MET): c.3334C> T (p.His1112Tyr) single nucleotide variant Likely pathogenic rs121913244 7:116417463-116417463 7:116777409-116777409
6 MET NM_001127500.3(MET): c.3803T> C (p.Met1268Thr) single nucleotide variant Likely pathogenic rs121913245 7:116423474-116423474 7:116783420-116783420
7 MTOR NM_004958.4(MTOR): c.7514G> C (p.Arg2505Pro) single nucleotide variant Likely pathogenic rs1057519777 1:11169361-11169361 1:11109304-11109304
8 MTOR NM_004958.4(MTOR): c.6667C> A (p.Gln2223Lys) single nucleotide variant Likely pathogenic rs1057519778 1:11182179-11182179 1:11122122-11122122
9 MET NM_001127500.3(MET): c.3742T> C (p.Tyr1248His) single nucleotide variant Uncertain significance rs121913247 7:116423413-116423413 7:116783359-116783359

Cosmic variations for Kidney Cancer:

9 (show top 50) (show all 260)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6941466 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 36
2 COSM14312 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 36
3 COSM14380 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 36
4 COSM18350 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 36
5 COSM17957 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 3:10142139-10142139 36
6 COSM14305 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 36
7 COSM14382 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 36
8 COSM25676 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 36
9 COSM17875 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 36
10 COSM17983 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 3:10149823-10149823 36
11 COSM18097 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.482G>A p.R161Q 3:10149805-10149805 36
12 COSM14425 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 36
13 COSM17872 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 36
14 COSM27269 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176L 3:124737785-124737785 36
15 COSM7349320 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1119+1G>T p.? 16:2060814-2060814 36
16 COSM7349613 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.976-1G>A p.? 16:2060669-2060669 36
17 COSM7349594 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 36
18 COSM7349602 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1636G>T p.E546* 16:2065555-2065555 36
19 COSM7349619 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.390C>G p.Y130* 16:2054349-2054349 36
20 COSM7349321 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1600-1G>T p.? 16:2065518-2065518 36
21 COSM7349621 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.774+1G>A p.? 16:2056770-2056770 36
22 COSM7349639 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.731G>T p.C244F 16:2056726-2056726 36
23 COSM7349636 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1189C>T p.Q397* 16:2061940-2061940 36
24 COSM6957851 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.541G>A p.V181M 16:2055461-2055461 36
25 COSM7349616 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1717-1G>C p.? 16:2070455-2070455 36
26 COSM1272079 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3412C>T p.R1138* 16:2080179-2080179 36
27 COSM6943738 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.975+1G>T p.? 16:2058874-2058874 36
28 COSM7349328 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1835T>A p.L612* 9:132905743-132905743 36
29 COSM7349331 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1276G>T p.D426Y 9:132907358-132907358 36
30 COSM6942356 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2287C>T p.Q763* 9:132902709-132902709 36
31 COSM6963117 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1001C>A p.S334* 9:132911481-132911481 36
32 COSM29770 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.508+1G>T p.? 9:132923347-132923347 36
33 COSM30474 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 36
34 COSM10656 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.742C>T p.R248W 17:7674221-7674221 36
35 COSM45243 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.374C>G p.T125R 17:7675995-7675995 36
36 COSM44310 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.738G>A p.M246I 17:7674225-7674225 36
37 COSM6922197 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.97-2A>C p.? 17:7676274-7676274 36
38 COSM45135 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.673-1G>T p.? 17:7674291-7674291 36
39 COSM10647 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.404G>T p.C135F 17:7675208-7675208 36
40 COSM6929752 TBX3 kidney,NS,carcinoma,renal cell carcinoma unclassified c.510G>T p.W170C 12:114681026-114681026 36
41 COSM6979493 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2096+1G>A p.? 23:124065947-124065947 36
42 COSM6975582 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1348A>T p.R450* 23:124057909-124057909 36
43 COSM6023628 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2860C>T p.R954C 23:124081464-124081464 36
44 COSM6963119 SPOP kidney,NS,carcinoma,renal cell carcinoma unclassified c.265T>G p.L89V 17:49619321-49619321 36
45 COSM6964939 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.987-2A>T p.? 22:23833570-23833570 36
46 COSM989 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1130G>A p.R377H 22:23834152-23834152 36
47 COSM1266238 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3575G>A p.R1192H 19:11033318-11033318 36
48 COSM6947611 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.863C>A p.S288* 3:47122264-47122264 36
49 COSM6975580 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.4736C>G p.S1579* 3:47062211-47062211 36
50 COSM4118007 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3266G>A p.R1089Q 3:47106061-47106061 36

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 MTOR MIR210 MIR21 MIR200C MIR17 MIR141
2 10.03 MEG3 HOTAIR

GO Terms for Kidney Cancer

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cellular response to hypoxia GO:0071456 9.63 MTOR MIR17 MALAT1
2 chromatin silencing GO:0006342 9.49 KCNQ1OT1 HOTAIR
3 negative regulation of stress fiber assembly GO:0051497 9.48 MIR21 MET
4 miRNA mediated inhibition of translation GO:0035278 9.46 MIR210 MIR21 MIR17 MIR106A
5 positive regulation of endothelial cell differentiation GO:0045603 9.43 MIR21 MIR200C
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.4 MIR21 MIR17
7 regulation of protein kinase B signaling GO:0051896 9.37 MTOR MIR21
8 positive regulation of metalloendopeptidase activity GO:1904685 9.32 MIR21 MIR17
9 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.26 MIR21 MET
10 gene silencing by miRNA GO:0035195 9.23 MIR210 MIR21 MIR200C MIR17 MIR141 MIR106A
11 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.13 MIR210 MIR21 MIR17

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR210 MIR21 MIR200C MIR17 MIR141 MIR106A

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....